
Sign up to save your podcasts
Or
Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.
Credit available for this activity expires: 10/18/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/982624?src=mkm_podcast_series_982624
4.2
2222 ratings
Newer oral glucose-lowering agents have revolutionized the treatment of type 2 diabetes (T2D), yet up to 40% of people across the globe still require insulin.
Credit available for this activity expires: 10/18/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/982624?src=mkm_podcast_series_982624
128 Listeners
39 Listeners
13 Listeners
318 Listeners
850 Listeners
478 Listeners
691 Listeners
16 Listeners
283 Listeners
251 Listeners
3,322 Listeners
92 Listeners
1,089 Listeners
173 Listeners
511 Listeners
320 Listeners
59 Listeners
8 Listeners
242 Listeners
364 Listeners